GBI Research, April 2011, Pages: 105
the Future to Counter Drying Pipelines”, provides insights into the global biotech M&A and licensingstrategies. The report provides an in-depth analysisofthe major M&A trends in the biotech industry
GBI Research, Sep 2011, Pages: 85
-Largest Pharmaceutical Market By 2013”, provides in-depth analysisof trends, issues and challenges in this industry. The report analyzes the effective strategies that shape the industry dynamics. Further
GBI Research, Feb 2012, Pages: 79
Healthcare Reform Plans Forecast to Slow Growth Rates” provides in-depth analysisof trends, issues and challenges in thepharmaceutical market in the Czech Republic. The report analyzes overall pharmaceutical
GBI Research, Dec 2011, Pages: 76
landscape, including thebenchmarkingoftopcompanies. Finally, key trends analysis on mergers and acquisitions, and licensing agreements involving pharmaceutical packaging is detailed.
This report is
GBI Research, Dec 2009, Pages: 62
analysisofthe competitive landscape, including thebenchmarkingoftopcompanies, key trends on mergers and acquisitions, and licensing agreements involving pharmaceutical packaging.
Global Pharmaceutical
GBI Research, Oct 2010, Pages: 120
: theUS, thetop five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes thelicensing
GBI Research, Nov 2011, Pages: 160
, investments and strategic partnerships
- Develop key strategic initiatives by studying the key strategiesoftop competitors
- Reinforce R&D pipelines by identifying licensingstrategies for acquiring new
GBI Research, Nov 2010, Pages: 85
Delivery Market.
Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report is
GBI Research, Oct 2011, Pages: 223
landscape, including topcompaniesbenchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.
The in
GBI Research, Sep 2011, Pages: 168
is based on propriety databases, primary and secondary research and in-house analysis by a team of experts.
Scope
The scope of this report includes:
- Strategies adopted by pharmaceutical and
GBI Research, Dec 2010, Pages: 97
analysisofthetopcompanies in the market. Finally, a key trend analysisof mergers and acquisitions, and licensing agreements in the contraceptives market is also included.
Scope
The scope of this
GBI Research, Aug 2010, Pages: 125
impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in theUS, thetop five countries in Europe (the UK, Germany, France
PharmaVentures, Jan 2009
Offerings
4.4 Exploitation Strategies
4.5 Business Models
4.6 Product, Strategy and Business Models for Drug Delivery Technology
4.7 Applicability to Segments ofthePharmaceutical Product Life Cycle
4.8
GBI Research, Feb 2010, Pages: 181
Analysis and R&D Pipeline”, which provides an insight into the global biotechnology industry and analyzes the competitive positioning ofthetop 10 companies in the industry. This pharmaceutical and
GBI Research, Dec 2009, Pages: 91
The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis “The Future of Global Vaccines - Market Forecasts to 2015, Stockpile
GBI Research, Sep 2011, Pages: 142
, erythropoietins and blood factors. Furthermore, it includes market forecasts for each therapeutic class. The report also explores the competitive landscape, with a competitive analysisofthetopcompanies in the
PharmaVentures, Oct 2006, Pages: 161
making activity ofthetop 10 pharmaceuticalcompanies by healthcare sales, and identifies the deals with which these companies have been engaged to help recognise potential partners amongst the largest
GBI Research, Aug 2010, Pages: 132
benchmarkingof leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
- Key M&A activities, licensing agreements, that
GBI Research, Feb 2010, Pages: 89
strategic initiatives by studying the key strategiesoftop competitors
- Identify potential SME companies that hold a lot of promise
- Reinforce R&D pipelines by identifying new target mechanisms which